Edinburgh, United Kingdom
Cytochroma, founded in 2017 and headquartered in the United Kingdom, is a pioneering player in the Biotechnology industry. With the slogan "Accelerating global drug development," the company excels in predicting how drugs will react across diverse global populations, whether in health or disease.
They've built a unique library of ethnically varied iPSC and automated cell culture technology to produce mature hepatocytes, which are essential for toxicity testing. Cytochroma focuses on supporting life science companies by de-risking drug compounds prior to clinical testing, making the drug development process faster, safer, and more efficient.
The company's most recent financial milestone was a £1.00M Seed Round investment on 16 December 2021, with contributions from Cambridge Capital Group, Angel Academe, and Investing Women. This strategic backing highlights investor confidence in Cytochroma's innovative approach and its potential to revolutionize drug development processes globally.
